{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T20:37:31Z","timestamp":1765485451780,"version":"build-2065373602"},"reference-count":157,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases","award":["R01-AR-054822"],"award-info":[{"award-number":["R01-AR-054822"]}]},{"DOI":"10.13039\/100000738","name":"Department of Veterans Affairs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001845","name":"Scleroderma Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001845","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.jaad.2010.04.026","type":"journal-article","created":{"date-parts":[[2010,7,3]],"date-time":"2010-07-03T04:34:40Z","timestamp":1278131680000},"page":"389-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Tyrosine kinases in inflammatory dermatologic disease"],"prefix":"10.1016","volume":"65","author":[{"given":"Ricardo T.","family":"Paniagua","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David F.","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorinda","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2010.04.026_bib1","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2010.04.026_bib2","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib3","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/13543784.13.7.743","article-title":"Targeting Syk as a treatment for allergic and autoimmune disorders","volume":"13","author":"Wong","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jaad.2010.04.026_bib4","doi-asserted-by":"crossref","first-page":"18895","DOI":"10.1073\/pnas.0810246105","article-title":"Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice","volume":"105","author":"Louvet","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2010.04.026_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrrheum.2009.82","article-title":"Tyrosine kinases as targets for the treatment of rheumatoid arthritis","volume":"5","author":"D'Aura Swanson","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/RHU.0b013e318188b1ce","article-title":"Maintained efficacy of the tyrosine kinase inhibitor imatinib mesylate in a patient with rheumatoid arthritis","volume":"14","author":"Eklund","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib7","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1172\/JCI28546.","article-title":"Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis","volume":"116","author":"Paniagua","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2010.04.026_bib8","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.jaad.2010.04.026_bib9","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","article-title":"The protein tyrosine kinase family of the human genome","volume":"19","author":"Robinson","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2010.04.026_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0092-8674(00)00114-8","article-title":"Cell signaling by receptor tyrosine kinases","volume":"103","author":"Schlessinger","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2010.04.026_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1146\/annurev.biochem.69.1.373","article-title":"Protein tyrosine kinase structure and function","volume":"69","author":"Hubbard","year":"2000","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.jaad.2010.04.026_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","article-title":"Tyrosine kinases as targets for cancer therapy","volume":"353","author":"Krause","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ni.1701","article-title":"Selectivity and therapeutic inhibition of kinases: to be or not to be?","volume":"10","author":"Ghoreschi","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583508004745","article-title":"Protein kinase inhibitors: contributions from structure to clinical compounds","volume":"42","author":"Johnson","year":"2009","journal-title":"Q Rev Biophys"},{"key":"10.1016\/j.jaad.2010.04.026_bib15","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jaad.2010.04.026_bib16","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"Gabrielli","year":"2009","journal-title":"Scleroderma. N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib17","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/art.11073","article-title":"Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population","volume":"48","author":"Mayes","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrc1434","article-title":"Switching on kinases: oncogenic activation of BRAF and the PDGFR family","volume":"4","author":"Dibb","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2010.04.026_bib19","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.jaad.2010.04.026_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/1523-1747.ep12276895","article-title":"Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma","volume":"92","author":"Gay","year":"1989","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib21","first-page":"1876","article-title":"Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma","volume":"22","author":"Ludwicka","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3181\/00379727-191-42880","article-title":"Increased plasma levels of platelet-derived growth factor activity in patients with progressive systemic sclerosis","volume":"191","author":"Pandolfi","year":"1989","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib23","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.1780331011","article-title":"Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis","volume":"33","author":"Klareskog","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0923-1811(98)00027-9","article-title":"Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma","volume":"18","author":"Zheng","year":"1998","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2010.04.026_bib25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1084\/jem.175.5.1227","article-title":"Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts","volume":"175","author":"Yamakage","year":"1992","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib26","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000111507","article-title":"The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study","volume":"216","author":"Soria","year":"2008","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2010.04.026_bib27","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF\u00a0receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib28","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/art.24365","article-title":"Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera","volume":"60","author":"Loizos","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1136\/ard.2007.085480","article-title":"Anti-PDGFR-alpha antibodies measured by non-bioactivity assays are not specific for systemic sclerosis","volume":"67","author":"Balada","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2010.04.026_bib30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.24381","article-title":"Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis","volume":"60","author":"Classen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","article-title":"Transforming growth factor beta as a therapeutic target in systemic sclerosis","volume":"5","author":"Varga","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.22328","article-title":"Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma","volume":"56","author":"Sonnylal","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib33","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature02006","article-title":"Smad-dependent and Smad-independent pathways in TGF-beta family signaling","volume":"425","author":"Derynck","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2010.04.026_bib34","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1172\/JCI200419603","article-title":"Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis","volume":"114","author":"Daniels","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2010.04.026_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1096\/fj.04-2733fje","article-title":"Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo","volume":"19","author":"Wang","year":"2005","journal-title":"FASEB J"},{"key":"10.1016\/j.jaad.2010.04.026_bib36","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1242\/jcs.02491","article-title":"Abl tyrosine kinase regulates a Rac\/JNK and a Rac\/Nox pathway for DNA synthesis and Myc expression induced by growth factors","volume":"118","author":"Boureux","year":"2005","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jaad.2010.04.026_bib37","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1128\/MCB.24.6.2573-2583.2004","article-title":"Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor","volume":"24","author":"Plattner","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jaad.2010.04.026_bib38","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/ncb1096","article-title":"Abl-dependent tyrosine phosphorylation of Sos-1 mediates growth-factor-induced Rac activation","volume":"6","author":"Sini","year":"2004","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jaad.2010.04.026_bib39","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1002\/art.24221","article-title":"Molecular framework for response to imatinib mesylate in systemic sclerosis","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib40","doi-asserted-by":"crossref","first-page":"G907","DOI":"10.1152\/ajpgi.00420.2004","article-title":"Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats","volume":"288","author":"Yoshiji","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jaad.2010.04.026_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.24186","article-title":"Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis","volume":"60","author":"Akhmetshina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib42","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/art.22314","article-title":"Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis","volume":"56","author":"Distler","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib43","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1096\/fj.07-105627","article-title":"Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis","volume":"22","author":"Akhmetshina","year":"2008","journal-title":"FASEB J"},{"key":"10.1016\/j.jaad.2010.04.026_bib44","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/art.23648","article-title":"Is imatinib mesylate a promising drug in systemic sclerosis?","volume":"58","author":"van Daele","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib45","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/rheumatology\/ken104","article-title":"Imatinib for the treatment of refractory, diffuse systemic sclerosis","volume":"47","author":"Sfikakis","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2010.04.026_bib46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s00392-009-0752-3","article-title":"Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension","volume":"98","author":"ten Freyhaus","year":"2009","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jaad.2010.04.026_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/rheumatology\/ken369","article-title":"A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide","volume":"48","author":"Sabnani","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2010.04.026_bib48","unstructured":"Pope J, McBain DL, Petrlich L, Watson S, Bender L, Deleon F, et\u00a0al. A\u00a0proof of concept trial of Gleevec (imatinib) in active diffuse scleroderma (DSSc) [abstract]. American College of Rheumatology (ACR)\/Association of Rheumatology Health Professionals (ARHP) Scientific Meeting 2009 [database online]. Philadelphia, PA; Accessed October 22, 2009."},{"key":"10.1016\/j.jaad.2010.04.026_bib49","unstructured":"Gordon J, Mersten J, Lyman S, Kloiber SA, Wildman HF, Crow MK, et\u00a0al. Imatinib mesylate (Gleevec) in the treatment of systemic sclerosis: interim results of a phase IIa, one year, open label clinical trial [abstract]. American College of Rheumatology (ACR)\/Association of Rheumatology Health Professionals (ARHP) Scientific Meeting 2009 [database online]. Philadelphia, PA; Accessed October 22, 2009."},{"key":"10.1016\/j.jaad.2010.04.026_bib50","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev.immunol.25.022106.141606","article-title":"Immunobiology of allogeneic hematopoietic stem cell transplantation","volume":"25","author":"Welniak","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib51","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib52","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/S0140-6736(09)60237-3","article-title":"Graft-versus-host disease","volume":"373","author":"Ferrara","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.04.026_bib53","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.bbmt.2008.10.016","article-title":"B cells and transplantation: an educational resource","volume":"15","author":"Small","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaad.2010.04.026_bib54","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jaad.2005.06.015","article-title":"Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: expanding the sclerodermoid spectrum","volume":"53","author":"Schaffer","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib55","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archderm.143.9.1157","article-title":"Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen UV-A therapy","volume":"143","author":"Creamer","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib56","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2007-01-071043","article-title":"Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease","volume":"110","author":"Svegliati","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2010.04.026_bib57","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2009-02-204156","article-title":"Imatinib for refractory chronic graft-versus-host disease with fibrotic features","volume":"119","author":"Olivieri","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2010.04.026_bib58","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(00)02694-5","article-title":"Scleromyxoedema-like cutaneous diseases in renal-dialysis patients","volume":"356","author":"Cowper","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2010.04.026_bib59","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.jacc.2008.12.061","article-title":"Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy","volume":"53","author":"Kribben","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaad.2010.04.026_bib60","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/archdermatol.2008.551","article-title":"Nephrogenic systemic fibrosis: late skin manifestations","volume":"145","author":"Bangsgaard","year":"2009","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib61","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.ajkd.2005.06.024","article-title":"Nephrogenic fibrosing dermopathy\/nephrogenic systemic fibrosis: report of a new case with literature review","volume":"46","author":"Daram","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaad.2010.04.026_bib62","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/01.bor.0000245725.94887.8d","article-title":"Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy)","volume":"18","author":"Galan","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib63","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.biocel.2003.10.005","article-title":"Circulating fibrocytes: collagen-secreting cells of the peripheral blood","volume":"36","author":"Quan","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.jaad.2010.04.026_bib64","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/art.20362","article-title":"Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin","volume":"50","author":"Jimenez","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib65","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1002\/art.23696","article-title":"Imatinib mesylate treatment of nephrogenic systemic fibrosis","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib66","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/j.ajkd.2008.08.029","article-title":"Imatinib in the treatment of nephrogenic systemic fibrosis","volume":"53","author":"Chandran","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jaad.2010.04.026_bib67","unstructured":"Kay J, Sullivan ME, Patel TV. Efficacy and safety of oral imatinib mesylate in patients with nephrogenic systemic fibrosis [abstract]. American College of Rheumatology (ACR)\/Association of Rheumatology Health Professionals (ARHP) Scientific Meeting 2009 [database online]. Philadelphia, PA; Accessed October 22, 2009."},{"key":"10.1016\/j.jaad.2010.04.026_bib68","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMra041320","volume":"352","author":"Schon","year":"2005","journal-title":"Psoriasis. N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib69","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nri1689","article-title":"Getting under the skin: the immunogenetics of psoriasis","volume":"5","author":"Bowcock","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib70","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nature03963","article-title":"Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins","volume":"437","author":"Zenz","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2010.04.026_bib71","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.4049\/jimmunol.178.7.4615","article-title":"Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation","volume":"178","author":"Boniface","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib72","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2353\/ajpath.2008.071074","article-title":"Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor","volume":"173","author":"Halin","year":"2008","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2010.04.026_bib73","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood-2003-08-2964","article-title":"Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia","volume":"104","author":"Kunstfeld","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2010.04.026_bib74","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/blood-2002-12-3793","article-title":"Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis","volume":"102","author":"Xia","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2010.04.026_bib75","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.febslet.2006.03.087","article-title":"Biology of vascular endothelial growth factors","volume":"580","author":"Roy","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jaad.2010.04.026_bib76","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0002-9440(10)61213-8","article-title":"Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes","volume":"167","author":"Wilgus","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jaad.2010.04.026_bib77","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1084\/jem.180.3.1141","article-title":"Overexpression of vascular permeability factor\/vascular endothelial growth factor and its receptors in psoriasis","volume":"180","author":"Detmar","year":"1994","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib78","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1582-4934.2007.00112.x","article-title":"Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF","volume":"12","author":"Man","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib79","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1600-0625.2005.00356.x","article-title":"Vascular endothelial growth factor 121 is the predominant isoform in psoriatic scales","volume":"14","author":"Zhang","year":"2005","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib80","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1046\/j.1365-2133.1999.03205.x","article-title":"Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis","volume":"141","author":"Bhushan","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib81","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/sj.jid.5701184","article-title":"The epidermal growth factor receptor system in skin repair and inflammation","volume":"128","author":"Pastore","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib82","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/sj.jid.5701135","article-title":"Betacellulin regulates hair follicle development and hair cycle induction and enhances angiogenesis in wounded skin","volume":"128","author":"Schneider","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib83","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1084\/jem.167.2.670","article-title":"Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes","volume":"167","author":"Gottlieb","year":"1988","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib84","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.2916128","article-title":"Overexpression of transforming growth factor alpha in psoriatic epidermis","volume":"243","author":"Elder","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.jaad.2010.04.026_bib85","first-page":"3224","article-title":"Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas","volume":"52","author":"Cook","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.jaad.2010.04.026_bib86","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/00000372-199604000-00010","article-title":"Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases","volume":"18","author":"Piepkorn","year":"1996","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.jaad.2010.04.026_bib87","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000070936","article-title":"Alteration and significance of heparin-binding epidermal-growth-factor-like growth factor in psoriatic epidermis","volume":"207","author":"Zheng","year":"2003","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2010.04.026_bib88","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jdermsci.2006.08.010","article-title":"Epiregulin, a member of the EGF family, is over-expressed in psoriatic epidermis","volume":"45","author":"Shirakata","year":"2007","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2010.04.026_bib89","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1172\/JCI119766","article-title":"Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype","volume":"100","author":"Cook","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2010.04.026_bib90","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000028031","article-title":"Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor","volume":"66","author":"Varani","year":"1998","journal-title":"Pathobiology"},{"key":"10.1016\/j.jaad.2010.04.026_bib91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000084909","article-title":"Antagonism of epidermal growth factor receptor tyrosine kinase ameliorates the psoriatic phenotype in organ-cultured skin","volume":"18","author":"Varani","year":"2005","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.jaad.2010.04.026_bib92","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib93","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-065X.2008.00644.x","article-title":"Therapeutic targeting of janus kinases","volume":"223","author":"Pesu","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaad.2010.04.026_bib94","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.4049\/jimmunol.0804063","article-title":"JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL\/J mice","volume":"183","author":"Chang","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib95","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1126\/science.1087061","article-title":"Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor","volume":"302","author":"Changelian","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jaad.2010.04.026_bib96","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/jid.2009.25","article-title":"Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis","volume":"129","author":"Boy","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib97","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.trsl.2007.01.003","article-title":"SU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis","volume":"149","author":"Keshtgarpour","year":"2007","journal-title":"Transl Res"},{"key":"10.1016\/j.jaad.2010.04.026_bib98","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1046\/j.1365-2133.2002.497217.x","article-title":"Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumor","volume":"147","author":"Miyagawa","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib99","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1346-8138.2007.00369.x","article-title":"Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib","volume":"34","author":"Woo","year":"2007","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib100","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1440-0960.2008.00495.x","article-title":"Management of imatinib-related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumor","volume":"50","author":"Cheng","year":"2009","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib101","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2230.2009.03250.x","article-title":"Imatinib: a designer drug, another cutaneous complication","volume":"34","author":"Dickens","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib102","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","article-title":"Mechanisms of cutaneous toxicities to EGFR inhibitors","volume":"6","author":"Lacouture","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2010.04.026_bib103","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2133.2006.07299.x","article-title":"Improvement of psoriasis and cutaneous side-effects during tyrosine kinase inhibitor therapy for renal metastatic adenocarcinoma: a role for epidermal growth factor receptor (EGFR) inhibitors in psoriasis?","volume":"155","author":"Wierzbicka","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib104","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3747\/co.v15i4.228","article-title":"Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis","volume":"15","author":"Neyns","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jaad.2010.04.026_bib105","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nrc1506","article-title":"Gefitinib\u2013a novel targeted approach to treating cancer","volume":"4","author":"Herbst","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaad.2010.04.026_bib106","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/00015550410024634","article-title":"Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor","volume":"84","author":"Zorzou","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2010.04.026_bib107","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMra061111","article-title":"Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome","volume":"355","author":"Stanley","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib108","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1172\/JCI10305","article-title":"Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions","volume":"106","author":"Nguyen","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2010.04.026_bib109","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198205203062001","article-title":"Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease","volume":"306","author":"Anhalt","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib110","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/08916930600971836","article-title":"Apoptotic mechanism in pemphigus autoimmunoglobulins-induced acantholysis\u2013possible involvement of the EGF receptor","volume":"39","author":"Frusic-Zlotkin","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaad.2010.04.026_bib111","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1600-0625.2009.00893.x","article-title":"An imbalance in Akt\/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris","volume":"18","author":"Pretel","year":"2009","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib112","doi-asserted-by":"crossref","first-page":"13804","DOI":"10.1074\/jbc.M611365200","article-title":"Desmoglein versus non-desmoglein signaling in pemphigus acantholysis: characterization of novel signaling pathways downstream of pemphigus vulgaris antigens","volume":"282","author":"Chernyavsky","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2010.04.026_bib113","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1074\/jbc.M209321200","article-title":"The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases","volume":"278","author":"Tatton","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2010.04.026_bib114","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1016\/S0021-9258(18)45614-1","article-title":"Genistein, a specific inhibitor of tyrosine-specific protein kinases","volume":"262","author":"Akiyama","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2010.04.026_bib115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2133.2004.06147.x","article-title":"In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades","volume":"151","author":"Sanchez-Carpintero","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib116","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2133.2008.08582.x","article-title":"The role of nitric oxide synthases in pemphigus vulgaris in a mouse model","volume":"159","author":"Marquina","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib117","doi-asserted-by":"crossref","first-page":"18303","DOI":"10.1074\/jbc.M710046200","article-title":"Pemphigus vulgaris IgG-induced desmoglein-3 endocytosis and desmosomal disassembly are mediated by a clathrin- and dynamin-independent mechanism","volume":"283","author":"Delva","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaad.2010.04.026_bib118","doi-asserted-by":"crossref","first-page":"12855","DOI":"10.1073\/pnas.0602973103","article-title":"p38MAPK inhibition prevents disease in pemphigus vulgaris mice","volume":"103","author":"Berkowitz","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2010.04.026_bib119","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib120","first-page":"148","article-title":"Bullous pemphigoid and pemphigus vulgaris: correlated behavior of serum VEGF, sE-selectin and TNF-alpha levels","volume":"11","author":"Ameglio","year":"1997","journal-title":"J Biol Regul Homeost Agents"},{"key":"10.1016\/j.jaad.2010.04.026_bib121","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/1523-1747.ep12606974","article-title":"Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme","volume":"104","author":"Brown","year":"1995","journal-title":"J Invest Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2010.04.026_bib122","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.jaad.2006.02.059","article-title":"Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib","volume":"56","author":"Hofmann","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib123","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000131751","volume":"10","author":"Krathen","year":"2008","journal-title":"Dermatomyositis. Curr Dir Autoimmun"},{"key":"10.1016\/j.jaad.2010.04.026_bib124","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.clindermatol.2006.07.014","article-title":"Lupus erythematosus: systemic and cutaneous manifestations","volume":"24","author":"Rothfield","year":"2006","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib125","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaad.2010.04.026_bib126","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/path.1721","article-title":"Enhanced type I interferon signaling promotes Th1-biased inflammation in cutaneous lupus erythematosus","volume":"205","author":"Wenzel","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.jaad.2010.04.026_bib127","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","article-title":"Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis","volume":"56","author":"Walsh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib128","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1365-2230.2006.02150.x","article-title":"Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis","volume":"31","author":"Wenzel","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib129","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BOR.0b013e32832e089e","article-title":"Type I interferon and lupus","volume":"21","author":"Ronnblom","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jaad.2010.04.026_bib131","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1074-7613(00)00055-8","article-title":"Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function","volume":"13","author":"Shimoda","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2010.04.026_bib132","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.4049\/jimmunol.166.9.5712","article-title":"A heritable defect in IL-12 signaling in B10.Q\/J mice. I: in vitro analysis","volume":"166","author":"Ortmann","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib133","doi-asserted-by":"crossref","first-page":"7776","DOI":"10.4049\/jimmunol.0900142","article-title":"A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis","volume":"182","author":"Spach","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib134","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.3899\/jrheum.081160","article-title":"Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus","volume":"36","author":"Hellquist","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0625.2009.00982.x","article-title":"Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus","volume":"19","author":"Jarvinen","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib136","doi-asserted-by":"crossref","first-page":"8145","DOI":"10.4049\/jimmunol.181.11.8145","article-title":"Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells","volume":"181","author":"Krishnan","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib137","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.23428","article-title":"An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus","volume":"58","author":"Bahjat","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib138","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.ki.5001528","article-title":"Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease","volume":"70","author":"Zoja","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jaad.2010.04.026_bib139","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1002\/art.21424","article-title":"Amelioration of autoimmune nephritis by imatinib in MRL\/lpr mice","volume":"52","author":"Sadanaga","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2010.04.026_bib140","first-page":"50","article-title":"Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concomitant sorafenib","volume":"32","author":"Apostolidis","year":"2009","journal-title":"Onkologie"},{"key":"10.1016\/j.jaad.2010.04.026_bib141","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1200\/JCO.2005.03.6913","article-title":"When does the presence of the target predict\u00a0response to the targeted agent?","volume":"24","author":"Bergsland","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2010.04.026_bib142","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1126\/science.1142946","article-title":"Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies","volume":"318","author":"Stommel","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jaad.2010.04.026_bib143","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI32479","article-title":"Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis","volume":"117","author":"Nissen","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2010.04.026_bib144","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1096\/fj.01-0847com","article-title":"Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus, and autoimmune mice","volume":"17","author":"Planque","year":"2003","journal-title":"FASEB J"},{"key":"10.1016\/j.jaad.2010.04.026_bib145","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2133.1988.tb03480.x","article-title":"Distribution of EGF receptor expressing and DNA replicating epidermal cells in psoriasis vulgaris and Bowen's disease","volume":"119","author":"Amagai","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib146","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1523-1747.ep12285389","article-title":"Altered [125I]epidermal growth factor binding and receptor distribution in psoriasis","volume":"86","author":"Nanney","year":"1986","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2010.04.026_bib147","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0923-1811(94)90021-3","article-title":"Differential expression of transforming growth factor-alpha (TGF-alpha) and EGF receptor in transitional area of psoriatic epidermis","volume":"7","author":"Higashiyama","year":"1994","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2010.04.026_bib148","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-0560.2007.00807.x","article-title":"Activation of Src-family tyrosine kinases in hyperproliferative epidermal disorders","volume":"35","author":"Ayli","year":"2008","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2010.04.026_bib149","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0560.2006.00590.x","article-title":"Srcasm overexpression in psoriasis-insights into pathogenesis","volume":"34","author":"Pulitzer","year":"2007","journal-title":"J Cutan Pathol"},{"key":"10.1016\/j.jaad.2010.04.026_bib150","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/kel449","article-title":"Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families","volume":"46","author":"Cunninghame Graham","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2010.04.026_bib151","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1086\/428480","article-title":"Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus","volume":"76","author":"Sigurdsson","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaad.2010.04.026_bib152","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1582-4934.2009.00500_1.x","article-title":"Nilotinib inhibits the Src-family kinase Lck and T-cell function in vivo","volume":"13","author":"Blake","year":"2008","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jaad.2010.04.026_bib153","doi-asserted-by":"crossref","first-page":"13283","DOI":"10.1073\/pnas.0702654104","article-title":"The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib","volume":"104","author":"Hantschel","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2010.04.026_bib154","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","article-title":"The Src\/Abl inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro","volume":"127","author":"Blake","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaad.2010.04.026_bib155","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2010.04.026_bib156","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/ncponc1156","article-title":"Drug insight: intracellular inhibitors of HER2\u2013clinical development of lapatinib in breast cancer","volume":"5","author":"Cameron","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.jaad.2010.04.026_bib157","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol Cancer Ther"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210005001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962210005001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:20:02Z","timestamp":1759270802000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962210005001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":157,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0190962210005001"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2010.04.026","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2011,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tyrosine kinases in inflammatory dermatologic disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2010.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}